GLP-1 RA Reduces Severity of Steatotic Liver Disease in People With HIV
By Elana Gotkine HealthDay Reporter
MONDAY, March 18, 2024 -- For people with HIV (PWH) with metabolic-associated steatotic liver disease (MASLD), semaglutide is associated with absolute and relative declines in intrahepatic triglyceride (IHTG) content, according to a study presented at the annual Conference on Retroviruses and Opportunistic Infections, held from March 3 to 6 in Denver.
Jordan E. Lake, M.D., from the University of Texas at Houston, and colleagues designed a phase 2b, single-arm, pilot study to examine the effects of semaglutide on magnetic resonance imaging-proton density fat fraction-quantified IHTG content in PWH and MASLD. Adult PWH on suppressive antiretroviral therapy with central adiposity, insulin resistance, or prediabetes and SLD received semaglutide for 24 weeks (49 participants).
The researchers found that semaglutide was well tolerated, with only two grade 3 and no grade 4 possibly related adverse events reported. The mean baseline IHTG was 12.7 percent; mean absolute and relative declines were –4.2 and –31.3 percent, respectively. Overall, 29 percent of participants had complete resolution of MASLD (absolute IHTG <5 percent), and 58 percent had a relative reduction of IHGT of ≥30 percent. For women, Hispanics, non-Hispanic Whites, and individuals with increasing age, there were trends seen toward greater improvements in IHTG. There were also significant improvements noted in weight, waist circumference, fasting glucose, and triglyceride concentrations. There was a correlation seen between improvements in IHTG and weight loss on semaglutide.
"Low-dose (1 mg weekly) semaglutide is a safe and effective pharmacologic therapy for MASLD in PWH and shows evidence of broader cardiometabolic benefit," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Semaglutide Alleviates Metabolic-Linked Liver Disease in People With HIV
TUESDAY, April 30, 2024 -- For people with HIV (PWH), semaglutide is effective for metabolic dysfunction-associated steatotic liver disease (MASLD), according to a research letter...
Cognitive Impairment Still Seen in Children, Teens With HIV
TUESDAY, April 30, 2024 -- Cognitive impairment persists in children and adolescents living with HIV even in the era of antiretroviral therapy (ART), according to research...
Pandemic Reignited Debate Regarding Physician's Obligation to Treat
MONDAY, April 29, 2024 -- There was a surge in ethics literature during COVID-19 advocating for the ethical acceptability of physicians refusing to treat, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.